Tools
Tizanidine
Indications
Tizanidine is a centrally acting alpha-2 agonist. Tizanidine is widely used as an anti-spastic agent for multiple medical conditions.
FDA-approved Indication
- Tizanidine is indicated for spasticity management due to multiple sclerosis, spinal cord injury, stroke, amyotrophic lateral sclerosis, and traumatic brain injury.[1][2][3]
Off-label Use
- Chronic neck and lower back pain[4]
- Rebound headaches due to analgesic withdrawal[5]
- Chronic migraine headaches[6]
- Refractory insomnia in spastic quadriplegic patients[7]
- Regional musculoskeletal pain syndromes[4]
Clinical Studies
- Placebo-controlled studies confirm the significant efficacy of tizanidine in reducing spasticity in patients with spinal cord-induced spasticity. Literature suggests that patients with severe spasticity are more likely to benefit from the therapy. Drug comparison studies have shown no differences in the efficacy of tizanidine compared with baclofen or diazepam. The tizanidine treatment group did not report increased weakness compared to the controls. Furthermore, patients given tizanidine experienced fewer adverse effects than those using controlled substances.[8]
- Studies exhibit that tizanidine, baclofen, and diazepam effectively decreased excessive muscle tone in patients with multiple sclerosis or cerebrovascular lesions. Muscle strength improved in all three treatment groups, but the improvement was most significant with tizanidine. Shakespeare et al. also reported similar findings showing no differences in efficacy between tizanidine, baclofen, and dantrolene compared to diazepam. However, diazepam was associated with more sedation.[9]
- Another study by Lataste et al. showed no significant differences between tizanidine and baclofen or diazepam for muscle tone, muscle spasms, clonus, muscle strength, or overall anti-spastic effect. However, tizanidine tolerance is slightly better than diazepam and baclofen.[10]
- Groves et al. report no significant differences between tizanidine, baclofen, or diazepam for spasticity by Ashworth score. However, applying global tolerability to treatment favored tizanidine compared to baclofen and diazepam.[11]
- Animal studies have shown that tizanidine provides benefits in the perioperative period and the management of neuropathic pain, such as trigeminal neuralgia, similar to the effects of clonidine under similar circumstances.
- A recent study indicates that tizanidine and other alpha-2 agonists can be used for medically supervised opioid withdrawal.[12]
- The American Academy of Neurology guidelines reports that tizanidine should be used for generalized spasticity in cerebral palsy, for segmental/localized spasticity treatment with botulinum toxin-A is more effective.[13]
Mechanism of Action
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Mechanism of Action
Tizanidine is an imidazoline derivative and a centrally acting alpha-2 receptor agonist. Tizanidine inhibits the release of excitatory amino acids like glutamate and aspartate from spinal interneurons. Consequently, tizanidine enhances the presynaptic inhibition of motor neurons. Tizanidine has significant action on spinal polysynaptic pathways.[14]
The overall effect of these actions is to reduce the facilitation of spinal motor neurons. Similarly, alpha-2 receptor-mediated inhibition of inter-neuronal activity appears to underlie tizanidine's additional anti-nociceptive and anti-convulsant activities. Spasm frequency and clonus are also reduced by tizanidine.[15]
Tizanidine also has an affinity for the alpha-1 receptors but to a lesser degree, which may explain its mild and transitory effect on the cardiovascular system compared to clonidine despite their structural and biochemical similarity.[16]
Pharmacokinetics
Absorption: Tizanidine has a significant, first-pass hepatic metabolism with an oral bioavailability of 20% to 34%. Tizanidine attains the steady-state concentration within 24 to 48 hours after administration. There is no noticeable change in its pharmacokinetic behavior with repeated intake.[17]
Distribution: Tizanidine has extensive tissue distribution; the volume of distribution is 2.4 L/kg. The plasma protein binding of tizanidine is approximately 30%.
Metabolism: Tizanidine is metabolized extensively in the liver by cytochrome P450-1A2 to inactive metabolites.
Excretion: Tizanidine has an elimination half-life of 2.5 hours, follows linear pharmacokinetics, and is excreted 60% through urine and 20% through feces.[18]
Administration
Tizanidine is administrated orally as 2 mg, 4 mg, and 6 mg capsules or as 2 mg and 4 mg tablets. Dosage starts with 2 mg orally and may repeat every 6 to 8 hours as needed. The dosage may gradually increase by 2 to 4 mg per dose for 1 to 4 days in between until there is a noticeably significant reduction of spasticity. Maximum dosing is three doses every 24 hours, up to 36 mg daily.
If tizanidine is used for more than nine weeks or given in high doses ranging from 20 mg to 36 mg daily, taper the dose gradually. The recommendation is to taper the dose to 2 to 4 mg daily to reduce the risk of tachycardia, rebound hypertension, and increased spasticity.[19]
The patient may open the capsule and sprinkle the contents into food. Patients can take tizanidine with food or on an empty stomach. It is important to note that the extent of absorption is greater when taken with food. The tablet and capsule dosage forms are not bioequivalent when administered with food. Hence, the clinician should counsel the patient to take tizanidine with or without food but be consistent to avoid fluctuations in concentration.[20] It is also important to recognize that smoking decreases tizanidine's plasma concentration and exposure(AUC).[21]
Use in Specific Patient Population
Patients with Hepatic Impairment: The consequence of Hepatic impairment on the pharmacokinetics of tizanidine has not been evaluated. However, tizanidine is extensively metabolized by the liver; therefore, hepatic impairment would significantly influence the pharmacokinetics of tizanidine. Therefore, tizanidine should be avoided or used with extreme caution in patients with hepatic impairment.
Patients with Renal Impairment: Tizanidine should be used cautiously in patients with renal impairment (creatinine clearance < 25 mL/min), as clearance is decreased by more than 50%. Start with a low dose, evaluate the response to therapy, and if a higher dose is needed, the dose can be increased rather than increasing the frequency of administration. The clinician should monitor the patient closely for adverse drug reactions such as dry mouth, drowsiness, asthenia, and dizziness as indicators of toxicity.
Pregnancy Considerations: The use of tizanidine in managing spinal cord injury during pregnancy has been described in case reports.[22] However, it is important to note that tizanidine is a former FDA pregnancy category-C and should be used only if indicated after careful risk-benefit evaluation.
Breastfeeding Considerations: Tizanidine is a lipid-soluble drug; hypothetically, it may be present in breast milk; its use during lactation is not advised.
Adverse Effects
Tizanidine is generally well-tolerated. However, reports exist of potential adverse effects on several organs, such as cutaneous, gastrointestinal, neurologic, cardiovascular, endocrine, and respiratory systems.
Common Adverse Drug Reactions
- Drowsiness
- Blurred vision
- Asthenia
- Constipation
- Dyskinesia
- Nervousness
- Hallucination
- Rhinitis
- Xerostomia[15]
- Dizziness[23]
Severe Adverse Drug Reactions
- Severe hepatotoxicity and liver failure[24]
- Anaphylaxis
- Exfoliative dermatitis
- Severe hypotension[25]
- QT interval prolongation[26]
- Severe bradycardia[27]
- Stevens-Johnson syndrome[28]
- Refractory hypokalemia and potassium wasting nephropathy[29]
Withdrawal Symptoms
- Tachycardia
- Rebound hypertension
- Increased spasticity
- Withdrawal symptoms are more likely to occur when discontinuing the drug abruptly.[19]
Drug Interactions
- Concomitant use of tizanidine with fluvoxamine or ciprofloxacin is contraindicated due to significant hypotension and increased psychomotor impairment.[30] A recent retrospective analysis of the WHO pharmacovigilance database identified severe cardiac and nervous system adverse drug reactions. The study concluded that the concomitant use of ciprofloxacin with tizanidine should be avoided.[31]
- Because of potential drug interactions, using tizanidine with other CYP1A2 inhibitors such as oral contraceptives containing Ethinyl estradiol and gestodene, dronedarone, pimozide, saquinavir, cimetidine, famotidine, acyclovir, and ticlopidine should be avoided due to decreased clearance of tizanidine.[32]
- If tizanidine is clinically necessary, therapy should be initiated with 2 mg and increased to 2 to 4 mg daily based on patient response to therapy.
- Adverse reactions such as hypotension, bradycardia, or excessive sedation require gradual dose reduction or stopping therapy.
- Tizanidine should be used cautiously in patients on other alpha-2 adrenergic receptor agonists.
- Patients should avoid alcohol and benzodiazepines with tizanidine as it can lead to excessive sedation and myocardial toxicity in rare instances.[33]
- Vemurafenib used in BRAF mutation-positive malignancy is an inhibitor of CYP1A2 and can increase plasma concentration of tizanidine, leading to potential toxicity.[34]
Contraindications
- Hypersensitivity to tizanidine or its ingredients is a contraindication to the use of tizanidine.
- Tizanidine use requires caution in patients with hepatic impairment. Review articles on tizanidine report cases of severe hepatotoxicity, acute liver failure, and death.[24]
- According to product labeling, tizanidine use requires caution in patients with renal impairment (creatinine clearance < 25 mL/min). In such patients, decrease the dose. If high doses are necessary, increase the individual dosage rather than the dosage frequency.
Monitoring
- Creatinine and liver function tests require measurement at baseline, then one month after the maintenance dose is achieved. Periodically monitor liver function tests in patients managed with tizanidine chronically and in higher doses.[24]
- Monitor blood pressure and heart rate before increasing the dosage because of the risk of severe hypotension associated with the higher dose.[25]
- Monitor the level of spasticity by Ashworth and modified Ashworth Scales.[35]
- In patients with multiple sclerosis, monitor spasticity using MS Spasticity Scale(MSSS-88).[36]
Toxicity
- The maximum recommended dose of tizanidine is 36 mg/day.[37]
- In the retrospective review, which included 45 patients, the mean dose ingested was 72 mg (Above the maximum recommended dose).
Clinical Features
- Lethargy
- Bradycardia
- Hypotension
- Agitation
- Confusion
- Vomiting
- Drowsiness
- Coma
Management
- There is no antidote for tizanidine toxicity.
- Tizanidine overdose management is by close monitoring of airways, administration of intravenous fluid, and vasopressors as necessary.[25]
- The pediatric case report described an overdose of tizanidine in spastic quadriplegia and toxicity presented with multiple organ dysfunction in the absence of sepsis.[37]
- A recent case report described the altered mental status and hemodynamic instability due to tizanidine overdose, and naloxone 10 mg IV administration improved Richmond Agitation-Sedation Scale(RASS).[38] The study concluded that naloxone could be used in tizanidine overdose in emergency settings; however, naloxone does not reverse the hemodynamic parameters.[39]
Enhancing Healthcare Team Outcomes
Tizanidine is a centrally acting alpha-2 agonist prescribed to manage spasticity caused by multiple sclerosis, stroke, and spinal cord injury. Tizanidine is also used off-label for managing patients suffering from chronic neck and back pain and chronic migraines. However, this drug can cause hypotension, bradycardia, and hepatotoxicity. Hence all healthcare providers need to understand indications, mechanisms, adverse effects, and their management.
The clinician prescribes tizanidine for appropriate indication and should assess liver function tests at baseline and one month. In addition, the neurologist should evaluate the improvement in spasticity related to neurological disorders such as multiple sclerosis, stroke, and spinal cord injury. Nurses can check compliance, monitor for adverse events, and counsel patients for adherence to therapy. The pharmacist should verify the dosing regimen, perform medication reconciliation for drug interactions, and counsel the patient on adverse drug reactions. In addition, patients need to be warned not to combine it with antihypertensive medications. In the overdose of tizanidine, triage nurses should admit the patient, and the emergency department physicians should monitor blood pressure and heart rate and obtain 12 lead EKG. Additionally, a liver function test is required to assess for hepatotoxicity. The critical care physician should manage severe overdose, which requires vasopressors and fluids during the ICU stay.
As depicted above, there are multiple healthcare providers, including clinicians (MDs, DOs, NPs, PAs), specialists, pharmacists, and nurses, involved in taking care of the patient. Tizanidine can be an effective therapeutic agent, but it requires the entire interprofessional healthcare team to collaborate and communicate for therapy to be successful. In addition, a recent study noted that interprofessional care between clinicians, neurologists, pharmacists, nurses, physical therapists, speech and language therapists, and occupational therapists is crucial for providing patient-centered care in patients with multiple sclerosis.[40] [Level 5]
References
Kamen L, Henney HR 3rd, Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Current medical research and opinion. 2008 Feb:24(2):425-39 [PubMed PMID: 18167175]
Level 3 (low-level) evidenceDorst J, Ludolph AC, Huebers A. Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis. Therapeutic advances in neurological disorders. 2018:11():1756285617734734. doi: 10.1177/1756285617734734. Epub 2017 Oct 9 [PubMed PMID: 29399045]
Level 3 (low-level) evidenceChang E, Ghosh N, Yanni D, Lee S, Alexandru D, Mozaffar T. A Review of Spasticity Treatments: Pharmacological and Interventional Approaches. Critical reviews in physical and rehabilitation medicine. 2013:25(1-2):11-22 [PubMed PMID: 25750484]
Malanga G, Reiter RD, Garay E. Update on tizanidine for muscle spasticity and emerging indications. Expert opinion on pharmacotherapy. 2008 Aug:9(12):2209-15. doi: 10.1517/14656566.9.12.2209. Epub [PubMed PMID: 18671474]
Level 3 (low-level) evidenceSmith TR. Low-dose tizanidine with nonsteroidal anti-inflammatory drugs for detoxification from analgesic rebound headache. Headache. 2002 Mar:42(3):175-7 [PubMed PMID: 11903539]
Yancey JR, Sheridan R, Koren KG. Chronic daily headache: diagnosis and management. American family physician. 2014 Apr 15:89(8):642-8 [PubMed PMID: 24784123]
Tanaka H, Fukuda I, Miyamoto A, Oka R, Cho K, Fujieda K. [Effects of tizanidine for refractory sleep disturbance in disabled children with spastic quadriplegia]. No to hattatsu = Brain and development. 2004 Nov:36(6):455-60 [PubMed PMID: 15560387]
Level 3 (low-level) evidenceWallace JD. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology. 1994 Nov:44(11 Suppl 9):S60-8; discussion S68-9 [PubMed PMID: 7970013]
Level 1 (high-level) evidenceShakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. The Cochrane database of systematic reviews. 2001:(4):CD001332 [PubMed PMID: 11687107]
Level 1 (high-level) evidenceLataste X, Emre M, Davis C, Groves L. Comparative profile of tizanidine in the management of spasticity. Neurology. 1994 Nov:44(11 Suppl 9):S53-9 [PubMed PMID: 7970011]
Level 1 (high-level) evidenceGroves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Advances in therapy. 1998 Jul-Aug:15(4):241-51 [PubMed PMID: 10186943]
Level 1 (high-level) evidenceSrivastava AB, Mariani JJ, Levin FR. New directions in the treatment of opioid withdrawal. Lancet (London, England). 2020 Jun 20:395(10241):1938-1948. doi: 10.1016/S0140-6736(20)30852-7. Epub [PubMed PMID: 32563380]
Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society, Delgado MR, Hirtz D, Aisen M, Ashwal S, Fehlings DL, McLaughlin J, Morrison LA, Shrader MW, Tilton A, Vargus-Adams J. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010 Jan 26:74(4):336-43. doi: 10.1212/WNL.0b013e3181cbcd2f. Epub [PubMed PMID: 20101040]
Level 2 (mid-level) evidenceFuchigami T, Kakinohana O, Hefferan MP, Lukacova N, Marsala S, Platoshyn O, Sugahara K, Yaksh TL, Marsala M. Potent suppression of stretch reflex activity after systemic or spinal delivery of tizanidine in rats with spinal ischemia-induced chronic spastic paraplegia. Neuroscience. 2011 Oct 27:194():160-9. doi: 10.1016/j.neuroscience.2011.08.022. Epub 2011 Aug 16 [PubMed PMID: 21871540]
Level 3 (low-level) evidenceWagstaff AJ, Bryson HM. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar:53(3):435-52 [PubMed PMID: 9074844]
Level 3 (low-level) evidenceCoward DM. Tizanidine: neuropharmacology and mechanism of action. Neurology. 1994 Nov:44(11 Suppl 9):S6-10; discussion S10-1 [PubMed PMID: 7970012]
Level 3 (low-level) evidenceTse FL, Jaffe JM, Bhuta S. Pharmacokinetics of orally administered tizanidine in healthy volunteers. Fundamental & clinical pharmacology. 1987:1(6):479-88 [PubMed PMID: 3447935]
Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. British journal of clinical pharmacology. 2004 Mar:57(3):349-53 [PubMed PMID: 14998432]
Suárez-Lledó A, Padullés A, Lozano T, Cobo-Sacristán S, Colls M, Jódar R. Management of Tizanidine Withdrawal Syndrome: A Case Report. Clinical medicine insights. Case reports. 2018:11():1179547618758022. doi: 10.1177/1179547618758022. Epub 2018 Feb 13 [PubMed PMID: 29467587]
Level 3 (low-level) evidenceHenney HR 3rd, Shah J. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects. Clinical therapeutics. 2007 Apr:29(4):661-9 [PubMed PMID: 17617289]
Level 1 (high-level) evidenceAl-Ghazawi M, Alzoubi M, Faidi B. Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. International journal of clinical pharmacology and therapeutics. 2013 Mar:51(3):255-62. doi: 10.5414/CP201790. Epub [PubMed PMID: 23380428]
Level 1 (high-level) evidenceQureshi AZ, Ullah S, AlSaleh AJ, Ullah R. Spinal cord injury during the second trimester of pregnancy. Spinal cord series and cases. 2017:3():17052. doi: 10.1038/scsandc.2017.52. Epub 2017 Aug 10 [PubMed PMID: 28808585]
Level 3 (low-level) evidenceSaper JR, Lake AE 3rd, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002 Jun:42(6):470-82 [PubMed PMID: 12167135]
Level 1 (high-level) evidence. Tizanidine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:(): [PubMed PMID: 31643379]
Spiller HA, Bosse GM, Adamson LA. Retrospective review of Tizanidine (Zanaflex) overdose. Journal of toxicology. Clinical toxicology. 2004:42(5):593-6 [PubMed PMID: 15462150]
Level 3 (low-level) evidenceKaddar N, Vigneault P, Pilote S, Patoine D, Simard C, Drolet B. Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr. Journal of cardiovascular pharmacology and therapeutics. 2012 Mar:17(1):102-9. doi: 10.1177/1074248410395020. Epub 2011 Feb 11 [PubMed PMID: 21317414]
Level 3 (low-level) evidenceKitabata Y, Orita H, Kamimura M, Shiizaki K, Narukawa N, Abe T, Kobata H, Akizawa T. Symptomatic bradycardia probably due to tizanidine hydrochloride in a chronic hemodialysis patient. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2005 Feb:9(1):74-7 [PubMed PMID: 15828911]
Level 3 (low-level) evidenceIshiguro A, Shibata T, Yanagishita T, Takama H, Uchida R, Ohshima Y, Watanabe D. A case of drug-induced Stevens-Johnson syndrome-like eruption predominating in mucosa: A case report. Clinical case reports. 2020 Aug:8(8):1379-1381. doi: 10.1002/ccr3.2806. Epub 2020 Jun 27 [PubMed PMID: 32884758]
Level 3 (low-level) evidenceBrucculeri MJ, Garcia J. Potassium wasting nephropathy in the setting of tizanidine overdose: a case report. Journal of medical case reports. 2021 May 1:15(1):250. doi: 10.1186/s13256-021-02811-8. Epub 2021 May 1 [PubMed PMID: 33931107]
Level 3 (low-level) evidenceGranfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clinical pharmacology and therapeutics. 2004 Dec:76(6):598-606 [PubMed PMID: 15592331]
Level 1 (high-level) evidenceRudolph A, Dahmke H, Kupferschmidt H, Burden A, Weiler S. Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database. European journal of clinical pharmacology. 2021 Jun:77(6):895-902. doi: 10.1007/s00228-020-02981-2. Epub 2021 Jan 6 [PubMed PMID: 33404754]
Level 2 (mid-level) evidenceChaugai S, Dickson AL, Shuey MM, Feng Q, Barker KA, Wei WQ, Luther JM, Stein CM, Chung CP. Co-Prescription of Strong CYP1A2 Inhibitors and the Risk of Tizanidine-Associated Hypotension: A Retrospective Cohort Study. Clinical pharmacology and therapeutics. 2019 Mar:105(3):703-709. doi: 10.1002/cpt.1233. Epub 2018 Oct 18 [PubMed PMID: 30223305]
Level 2 (mid-level) evidenceAmino M, Yoshioka K, Ikari Y, Inokuchi S. Long-term myocardial toxicity in a patient with tizanidine and etizolam overdose. Journal of cardiology cases. 2016 Mar:13(3):78-81. doi: 10.1016/j.jccase.2015.10.009. Epub 2015 Nov 28 [PubMed PMID: 30546611]
Level 3 (low-level) evidenceZhang W, McIntyre C, Riehl T, Forbes H, Bertran E, Choi HJ, Lee DH, Lee J. Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAF(V600) Mutation-Positive Malignancies. Clinical pharmacology in drug development. 2020 Jul:9(5):651-658. doi: 10.1002/cpdd.788. Epub 2020 Apr 20 [PubMed PMID: 32311241]
Meseguer-Henarejos AB, Sánchez-Meca J, López-Pina JA, Carles-Hernández R. Inter- and intra-rater reliability of the Modified Ashworth Scale: a systematic review and meta-analysis. European journal of physical and rehabilitation medicine. 2018 Aug:54(4):576-590. doi: 10.23736/S1973-9087.17.04796-7. Epub 2017 Sep 13 [PubMed PMID: 28901119]
Level 1 (high-level) evidenceHui D, Argáez C. Onabotulinum Toxin A (Botox) for Spasticity Associated With Multiple Sclerosis. 2021 Mar:(): [PubMed PMID: 34260163]
Vila J, Morgenstern A, Vendrell L, Ortega J, Danés I. Liver, Renal, and Cardiovascular Failure After Unintentional Overdose of Tizanidine in a 2-Year-Old Child. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. 2021:26(6):643-646. doi: 10.5863/1551-6776-26.6.643. Epub 2021 Aug 16 [PubMed PMID: 34421416]
Kerson AG, DeMaria R, Mauer E, Joyce C, Gerber LM, Greenwald BM, Silver G, Traube C. Validity of the Richmond Agitation-Sedation Scale (RASS) in critically ill children. Journal of intensive care. 2016:4():65 [PubMed PMID: 27800163]
Adams A, Copley C. High dose naloxone for acute tizanidine overdose in the emergency department: a case report. Clinical toxicology (Philadelphia, Pa.). 2021 Aug:59(8):764-765. doi: 10.1080/15563650.2020.1863977. Epub 2021 Jan 6 [PubMed PMID: 33403870]
Level 3 (low-level) evidenceSchmid F, Rogan S, Glässel A. A Swiss Health Care Professionals' Perspective on the Meaning of Interprofessional Collaboration in Health Care of People with MS-A Focus Group Study. International journal of environmental research and public health. 2021 Jun 17:18(12):. doi: 10.3390/ijerph18126537. Epub 2021 Jun 17 [PubMed PMID: 34204475]
Level 3 (low-level) evidence